Skip to content

4885.T

MUROMACHI CHEMICALS INC.

スタンダード · 医薬品 · 医薬品 · JP

JPY 899.00
−0.11%
Ask drillr

Year over year

Reported trailing growth

Revenue
+10.6%
EBITDA
—
EBIT
+24.0%
EPS
-15.7%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+3.1%
EBITDA
—
EPS
+42.2%

Three-year CAGR

Revenue
+5.4%
EBITDA
+3.3%
EBIT
-0.4%
Net income
-19.1%
EPS
-21.3%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Feb 1, 2026